Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs

References

• Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat Rev. 2019;74:49–60.
   PubMed Web of Science ®Google Scholar
• Haanen JB, Robert C. Immune checkpoint inhibitors. Prog Tumor Res. 2015;42:55–66.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Imbimbo M, Malouf R, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. The Cochrane Database of Systematic Reviews. 2020;12: cd013257.
   PubMedGoogle Scholar
• Yoneda K, Imanishi N, Ichiki Y, et al. Immune checkpoint inhibitors (ICIs) in Non-Small cell lung cancer (NSCLC). J Uoeh. 2018;40(2):173–189.
   PubMedGoogle Scholar
• Yi M, Yu S, Qin S, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):47.
   PubMedGoogle Scholar
• O'Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970.
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Y, Zhang S, et al. Gut microbiota-mediated immunomodulation in tumor. J Exp Clin Cancer Res. 2021;40(1):221.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156–1160.
   PubMed Web of Science ®Google Scholar
• Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl 1):e12405.
   Web of Science ®Google Scholar
• Ocáriz-Díez M, Cruellas M, Gascón M, et al. Microbiota and lung cancer. Opportunities and challenges for improving immunotherapy efficacy. Front Oncol. 2020;10:568939.
   PubMed Web of Science ®Google Scholar
• Konstantinidis T, Tsigalou C, Karvelas A, et al. Effects of antibiotics upon the gut microbiome: a review of the literature. Biomedicines. 2020;8(11):502.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee JE, Hong SH, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer. 2019;19:1100.
   PubMed Web of Science ®Google Scholar
• Tinsley N, Zhou C, Tan G, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist. 2020;25(1):55–63.
   PubMed Web of Science ®Google Scholar
• Patel P, Poudel A, Kafle S, et al. Influence of microbiome and antibiotics on the efficacy of immune checkpoint inhibitors. Cureus. 2021;13(8):e16829.
   PubMed Web of Science ®Google Scholar
• Routy B, Chatelier EL, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084.
   PubMed Web of Science ®Google Scholar
• Schwartz DJ, Rebeck ON, Dantas G. Complex interactions between the microbiome and cancer immune therapy. Crit Rev Clin Lab Sci. 2019;56(8):567–585.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–1133.e1117.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai Z, Yan C, et al. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. Clin Transl Oncol. 2021;23(12):2415–2430.
   PubMed Web of Science ®Google Scholar
• Wu Q, Liu J, Wu S, et al. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: a study based on 44 cohorts. Int Immunopharmacol. 2021;92:107303.
   PubMed Web of Science ®Google Scholar
• Sen S, Carmagnani Pestana R, Hess K, et al. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Ann Oncol. 2018;29(12):2396–2398.
   PubMed Web of Science ®Google Scholar
• Kulkarni AA, Ebadi M, Zhang S, et al. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. ESMO Open. 2020;5(5):e000803.
   PubMed Web of Science ®Google Scholar
• Zhou J, Huang G, Wong WC, et al. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors. Front Immunol. 2022;13:968729.
   PubMedGoogle Scholar
• Karam JD, Noel N, Voisin AL, et al. Infectious complications in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020;141:137–142.
   PubMed Web of Science ®Google Scholar
• Zhao S, Gao G, Li W, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–17.
   PubMed Web of Science ®Google Scholar
• Hu H, Dong Z, Tan P, et al. Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Oncotarget. 2016;7(3):3171–3185.
   PubMedGoogle Scholar
• Yang J, Dong Z, Ren A, et al. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2020;24(7):4245–4260.
   PubMed Web of Science ®Google Scholar
• Merino M, Lozano T, Casares N, et al. Dual activity of PD-L1 targeted doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnology. 2021;19(1):102.
   PubMed Web of Science ®Google Scholar
• Shan CK, Du YB, Zhai XT, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8(+) T cell augmentation. Cancer Chemother Pharmacol. 2021;87(3):425–436.
   PubMed Web of Science ®Google Scholar
• Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.
   PubMed Web of Science ®Google Scholar
• Lu PH, Tsai TC, Chang JW, et al. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in asia. J Clin Pharm Ther. 2021;46(2):408–414.
   PubMed Web of Science ®Google Scholar
• Acharya M, Kim T, Li C. Broad-Spectrum antibiotic use and disease progression in Early-Stage melanoma patients: a retrospective cohort study. Cancers (Basel). 2021;13(17):4367. ).
   PubMed Web of Science ®Google Scholar
• Pérez-Ruiz E, Jiménez-Castro J, Berciano-Guerrero MA, et al. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. Clin Transl Oncol. 2020;22(10):1778–1785.
   PubMed Web of Science ®Google Scholar
• Chen H, Han KD, He ZJ, et al. How to choose a survival period? The impact of antibiotic use on OS or PFS in NSCLC patients treated with immune checkpoint inhibitors: a systematic review and Meta-Analysis. Technol Cancer Res Treat. 2021;20:15330338211033498.
   Web of Science ®Google Scholar
• Chambers LM, Michener CM, Rose PG, et al. Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. Gynecol Oncol. 2021;161(1):211–220.
   PubMed Web of Science ®Google Scholar
• Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab. Anticancer Res. 2017;37:3195–3200.
   PubMed Web of Science ®Google Scholar
• Iglesias-Santamaría A. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol. 2020;22(9):1481–1490.
   PubMed Web of Science ®Google Scholar
• Yang M, Wang Y, Yuan M, et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: an up-to-date systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106876.
   PubMed Web of Science ®Google Scholar
• Meriggi F, Zaniboni A. Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. Cancer Immunol Immunother. 2021;70(6):1511–1517.
   PubMed Web of Science ®Google Scholar
• Xu H, Xu X, Wang H, et al. The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;149:102909.
   PubMed Web of Science ®Google Scholar
• Schett A, Rothschild SI, Curioni-Fontecedro A, et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol. 2020;85(1):121–131.
   PubMed Web of Science ®Google Scholar
• Hamada K, Yoshimura K, Hirasawa Y, et al. Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy. Anticancer Res. 2021;41(10):4985–4993.
   PubMed Web of Science ®Google Scholar
• Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021;149:73–81.
   PubMed Web of Science ®Google Scholar
• Lurienne L, Cervesi J, Duhalde L, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and Meta-Analysis. J Thorac Oncol. 2020;15(7):1147–1159.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Maio MD, Nigro O, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4):9.
   Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, KEYNOTE-189 Investigators, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Mohiuddin JJ, Chu B, Facciabene A, et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J Natl Cancer Inst. 2021;113(2):162–170.
   PubMedGoogle Scholar
• Elkrief A, Raichani LE, Richard C, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(4):e1568812.
   PubMed Web of Science ®Google Scholar
• Swami U, Chennamadhavuni A, Borcherding N, et al. Multivariable analysis of 169 cases of advanced cutaneous melanoma to evaluate antibiotic exposure as predictor of survival to anti-PD-1 based immunotherapies. Antibiotics (Basel). 2020;9:740.
   PubMed Web of Science ®Google Scholar
• Lalani AA, Xie W, Braun DA, et al. Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur Urol Oncol. 2020;3(3):372–381.
   PubMed Web of Science ®Google Scholar
• Ueda K, Yonekura S, Ogasawara N, et al. The impact of antibiotics on prognosis of metastatic renal cell carcinoma in japanese patients treated with immune checkpoint inhibitors. Anticancer Res. 2019;39(11):6265–6271.
   PubMed Web of Science ®Google Scholar
• Tsikala-Vafea M, Belani N, Vieira K, et al. Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Int J Infect Dis. 2021;106:142–154.
   PubMed Web of Science ®Google Scholar
• Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226:108707.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Jr., et al. PD-1 blockade in tumors with Mismatch-Repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Tolba MF. Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors. Int J Cancer. 2020;147(11):2996–3006.
   PubMed Web of Science ®Google Scholar
• Velikova T, Krastev B, Lozenov S, et al. Antibiotic-Related changes in microbiome: the hidden villain behind colorectal carcinoma immunotherapy failure. IJMS. 2021;22(4):1754.
   Google Scholar
• Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study. Gut. 2019;68(11):1971–1978.
   PubMed Web of Science ®Google Scholar
• Jing N, Wang L, Zhuang H, et al. Sex-Biased immune responses to antibiotics during anti-PD-L1 treatment in mice with Colon cancer. J Immunol Res. 2022;2022:9202491.
   PubMed Web of Science ®Google Scholar
• McKee AM, Hall LJ, Robinson SD. The microbiota, antibiotics and breast cancer. Breast Cancer Manag. 2019;8(3):Bmt29.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen N, Gao Y, et al. Clinical progress of PD-1/L1 inhibitors in breast cancer immunotherapy. Front Oncol. 2021;11:724424.
   PubMed Web of Science ®Google Scholar
• Simin J, Tamimi RM, Engstrand L, et al. Antibiotic use and the risk of breast cancer: a systematic review and dose-response meta-analysis. Pharmacol Res. 2020;160:105072.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yu L, Shi J, et al. Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis. Sci Rep. 2021;11(1):14024.
   PubMed Web of Science ®Google Scholar
• Toumazi D, Daccache SE, Constantinou C. An unexpected link: the role of mammary and gut microbiota on breast cancer development and management (review). Oncol Rep. 2021;45(5):80.
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Kichenadasse G, Karapetis CS, et al. Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab. Eur Urol. 2020;78(4):540–543.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–1778.
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444.
   PubMed Web of Science ®Google Scholar
• Guo JC, Lin CC, Lin CY, et al. Neutrophil-to-lymphocyte ratio and use of antibiotics associated with prognosis in esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitors. Anticancer Res. 2019;39(10):5675–5682.
   PubMed Web of Science ®Google Scholar
• Castello A, Rossi S, Toschi L, et al. Impact of antibiotic therapy and metabolic parameters in Non-Small cell lung cancer patients receiving checkpoint inhibitors. J Clin Med. 2021;10(6):1251.
   Web of Science ®Google Scholar
• Guven DC, Acar R, Yekeduz E, et al. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. Curr Probl Cancer. 2021;45(6):100760.
   PubMed Web of Science ®Google Scholar